Meta’s $65B AGI Bet, Bold Biology, and the Future of Feel-Good Infrastructure
Tuesday Current (July 1, 2025): While AI grabs the headlines, there's also momentum flowing through medtech, mitochondria, and shelf-stable juice..
Startup Deal Desk is Powered by ThinkFISH
We're halfway through 2025, and while AI continues to dominate headlines, this week’s energy is moving through medtech, molecular health, and the science of how we feel. Please subscribe if you haven’t already.
For biotech and CPG investors, the message is clear: infrastructure matters - whether it’s smarter surgery, mitochondrial medicine, or wellness brands built to scale.
Here's what's moving:
⚡️MAKING WAVES
Meta’s $65B AGI Bet Goes Live – Meta launches Superintelligence Labs with Alexandr Wang and Nat Friedman, raising $29B for U.S. data centers and poaching OpenAI talent
Abridge Raises $300M for AI Medical Scribes – With $117M in ARR and deep Epic integration, Abridge is scaling fast and expanding into medical coding
Neuron23 Closes $96.5M to Tackle Parkinson’s – A bet on early-stage neurodegeneration using pharma + digital diagnostics
Aria Growth Raises $152M for Better-for-You CPG – A strong signal: functional brands built for grocery are still outperforming DTC buzz
Gallant Pulls $18M for Pet Stem Cell Therapies – Backed by Digitalis, Gallant shows biotech’s expansion beyond traditional categories
ForSight Robotics Raises $125M – Robotic cataract surgery is now center stage as AI + hardware converge in medtech
Loom: Juice from the Future™
Company Overview: Loom is a next-gen wellness beverage brand reinventing juice for today’s health-conscious, culture-driven consumer. Founded by second-generation industry veterans whose family helped bring brands like Bai, Vita Coco, and Celsius to market. Loom is backed by decades of distribution insight and built to scale. Loom’s shelf-stable juice water blends real-fruit taste with a fraction of the sugar found in traditional juice. 🔗 Company LinkedIn
Each bottle is Non-GMO, gluten-free, vegan, kosher, and certified Plastic Neutral. Think of it as Poppy meets Liquid Death with a clean-label mission and media-worthy cultural momentum.
Why Investors Are Paying Attention
Named “Best New Brand” by BevNET and featured in Rolling Stone and Sports Illustrated.
On shelves at ShopRite, the Northeast’s largest grocery chain, plus 3,000+ independents and expanding.
Certified Plastic Neutral and aligned with ESG-aligned investment theses.
🔗 Pitch Deck 🔗 One Pager 🔗 Founder LinkedIn 🔗 Book an Intro Call
Adjuvia Therapeutics
Company Overview: At Adjuvia, the mission is deeply personal: to bring real treatments to patients facing devastating rare diseases that rob them of time, mobility, and life itself. Adjuvia’s first focus is on two fatal childhood diseases Friedreich’s Ataxia and Leigh Syndrome caused by a breakdown in the mitochondria, the “powerhouse” of our cells. These aren’t just complicated medical conditions. They are diagnoses that leave families with few answers and no cures. The team at Adjuvia is developing a gentle, oral therapy made from one of nature’s most powerful antioxidants.
This treatment, called ATI-103, is designed to go straight to the damaged mitochondria and give cells a chance to repair, recover, and function again. While the science is exciting, the heart behind the company is what drives it: a belief that patients deserve more than hope, they deserve healing.
Why Investors Are Paying Attention
Clinical trials planned with CHOP, one of the world’s leading children’s hospitals for rare disease Protected by strong patents, covering both the ingredient and how it’s made
Led by a founder with a track record, Dr. Laura Hix Glickman previously raised $34M to bring another therapy into the clinic
Built for long-term impact, with potential to expand into autism, aging, and neurodegenerative conditions where mitochondrial repair may help
🔗 One Pager 🔗 Founder LinkedIn 🔗 Company LinkedIn 🔗 Book an Intro Call
This week’s top stories remind us:
Tech doesn’t win on hype, it wins on delivery. Whether you're building rare disease therapies that integrate with top-tier clinics or wellness brands that move through real-world distribution - traction follows infrastructure, not noise.
For medtech and wellness founders:
If you’re regulatory-and-retail-ready, you’re in demand.
If you’re solving for access, not just optics, you’re where capital is headed.
Let us know if you’re raising or scouting - we’re plugged in!
Want to explore more? Reef Exclusive Perks. Contact us.
Stay tuned for Friday, when we go deeper into the founder journeys of Loom and Adjuvia Therapeutics.